Ipca Laboratories Ltd.
IPCALAB · ISIN: INE571A01038
Ipca Laboratories Ltd. is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE571A01038.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.14%), NIFTY LMC 250 TRI (0.33%), NIFTY MC 150 TRI (0.67%)
CHART
Ipca Laboratories Ltd. - growth of ₹100
Growth of ₹100 invested on 2026-09-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-0.04%
3M
+10.21%
6M
+25.82%
1Y
+51.82%
3Y CAGR
+25.1%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Ipca Laboratories Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
F&O Sentiment
Nearest expiry: 2025-02-27 · As of 2025-02-27.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2022-01-10 | SPLIT | 0.500000 | FACE VALUE SPLIT (SUB-DIVISION) - FROM RS 2/- PER SHARE TO RE 1/- PER SHARE |
Recent Deals
No recent block/bulk/short-sell deals on record for this stock.
Frequently asked questions
What is Ipca Laboratories Ltd.'s 1-year and 3-year return?
Ipca Laboratories Ltd.'s 1-year price return is +51.82%. Its 3-year CAGR (annualized return) is +25.1%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Ipca Laboratories Ltd.'s latest financial performance?
Ipca Laboratories Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹10,126 Cr, with a TTM profit after tax of ₹1,375 Cr and an EBITDA margin of 18.6%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹51.63, with a 5-year EPS growth rate of 5.92% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Ipca Laboratories Ltd.'s quality score?
Ipca Laboratories Ltd. has a Punji quality score of 72.7 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Ipca Laboratories Ltd.'s technical indicators show?
As of 2026-10-29, Ipca Laboratories Ltd.'s RSI (14-day) is 50.19 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Ipca Laboratories Ltd.?
As of 2026-06-30, Ipca Laboratories Ltd.'s shareholding is split across Promoter (44.72%), Public (55.28%). Promoter holding of 44.72% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Ipca Laboratories Ltd. part of any major market index?
Yes - Ipca Laboratories Ltd. is a constituent of NIFTY 500 TRI (0.14% weight) and NIFTY LMC 250 TRI (0.33% weight) and NIFTY MC 150 TRI (0.67% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
What does the F&O market show for Ipca Laboratories Ltd.?
As of 2025-02-27 (nearest expiry 2025-02-27), Ipca Laboratories Ltd.'s put-call ratio by open interest is 0.752 - below 1, typically read as bullish positioning (more open interest on calls than puts). The max pain strike is ₹1460, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
What corporate actions has Ipca Laboratories Ltd. announced recently?
The most recent corporate action for Ipca Laboratories Ltd. is a SPLIT (0.500000) with an ex-date of 2022-01-10, for: FACE VALUE SPLIT (SUB-DIVISION) - FROM RS 2/- PER SHARE TO RE 1/- PER SHARE. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns